Row over patent plan for medicinal plants
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.THREE multinational companies are being accused of "biopiracy" after taking out patents covering uses of three plants commonly used for herbal medicine treatments in India. One of the companies retorted that the accusations are part of an attempt by the Indian government to claim plants and treatments widely used across the Far East originated in India, so that companies there can patent them instead.
The plants - dudhi (Euphorbia hirta), black nightshade (Solanum nigrum), and chhotagokhuru (Tribulus terrestris) - are used to treat conditions including worm infestation, stomach irritation, menstrual pain and urinary infections.
In the US, Proctor & Gamble, Phytopharm and Zeneca have registered patents covering various uses of general extracts and specific chemicals from the plants. They include "pharmaceutical compositions for the treatment of skin disorders" and "for gastro-protection". These would include the ways Indians now use the plants, or their extracts.
The Gaia Foundation pressure group condemned the move as "prospecting for green gold", in which companies hope to patent medicines used for centuries by Indian practitioners. But Richard Dixey, chief executive of Huntingdon-based Phytopharm, accused the group of "flag-waving" and India of sabre-rattling.
"We use Tribulus as a component of a formulation that comes from China," he said. "India is trying to lay claim to ownership of plants that are distributed all over the Far East. But Tribulus is one of 10 components of our own product which we source in China. We buy tonnes of it - earning that country very good money."
Patenting plants and indigenous naturally occurring chemicals has become increasingly contentious. Biotechnology companies say patents are necessary to protect the investment made to discover the active chemicals or genes, and that the patents only cover specified applications of those discoveries. They also point out that patents are public, and have a limited lifespan.
Vandana Shiva, of the Indian Research Foundation for Science, Technology and Ecology said: "Since all these plants' properties have been systematically studied within our indigenous knowledge systems ... claims to novelty, on which the patents are based, are false."
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments